Fruquintinib Combined With Chemotherapy as Third-line /Third-line+ Treatment in Advanced Colorectal Cancer

Launched by ZHEJIANG CANCER HOSPITAL · Jun 29, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at a new treatment option for patients with advanced colorectal cancer who have already received two previous treatments without success. The study will explore the effectiveness and safety of a drug called fruquintinib when combined with chemotherapy. This treatment is specifically for adults aged 18 and older who have been diagnosed with advanced metastatic colorectal adenocarcinoma, which means the cancer has spread beyond the colon or rectum. To qualify for the trial, participants must have had a good response to their initial chemotherapy and must have measurable cancer that can be assessed.

Participants in this study can expect to receive close monitoring and care throughout the trial. They will need to meet specific health criteria, such as having a certain level of blood cell counts and organ function. It's also important for potential participants to understand that they will need to sign consent forms, confirming that they understand the study and agree to take part. This trial is not yet recruiting participants, so there will be some time before it starts. If you or someone you know is interested in participating, it may be a good idea to talk with a healthcare provider for more information.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Have fully understood the study and voluntarily signed the informed consent
• • 2. Age ≥18 years old, male or female
• • 3. Advanced metastatic colorectal adenocarcinoma confirmed by histopathology
• • 4. The best efficacy evaluation of first-line chemotherapy (mFOLFOX6, XELOX, or FOLFIRI) in previous patients must be partial response (PR) or above or progression-free survival (PFS) ≥1 year, with a first-line drug withdrawal interval of more than 1 year. Pre-adjuvant/neoadjuvant therapy is allowed. If recurrence or metastasis occurs during or within 6 months after completion of adjuvant/neoadjuvant therapy, adjuvant/neoadjuvant therapy is considered a failure of first-line chemotherapy for advanced disease
• • 5. The patient has failed at least previous second-line treatment，The use of Cetuximab (KRAS and Braf wild type) and bevacizumab in previous anti-tumor regiments is required，Prior treatment with regorafenib or TAS-102 is permitted
• • 6. ECOG status 0-2 points
• • 7. Expected survival ≥12 weeks
• • 8. Have at least one measurable lesion (RECIST version 1.1)
• • 9. Inadequate bone marrow reserve or organ function, as demonstrated by any of the following laboratory values: Absolute neutrophil count (ANC) ≥1.5×109/L Platelet count ≥80×109 / L Hemoglobin≥80 g/L（\<8 g/dL） Serum albumin ≥3g/dL Alanine aminotransferase \<2.5 × upper limit of normal (ULN) if no demonstrable liver metastases or \<5 × ULN in the presence of liver metastases. Aspartate aminotransferase (AST) \<2.5 × ULN if no demonstrable liver metastases or \< 5 × ULN in the presence of liver metastases. Total bilirubin (TBL)\<1.5 × ULN Creatinine≤ 1.5 × ULN concurrent with creatinine clearance ≤50 mL/min (measured or calculated by the Cockcroft-Gault equation) confirmation of creatinine clearance is only required when creatinine is ≤1.5 × ULN.
• • 10. Fertile male or female patients voluntarily used effective contraceptive methods, such as double barrier methods, condoms, oral or injectable contraceptives, intrauterine devices, etc., during the study period and within 6 months of the last study dose. All female patients will be considered fertile unless they have undergone natural menopause, artificial menopause, or sterilization (such as hysterectomy, bilateral adnexectomy, or irradiation of radioactive ovaries).
• • 11. Good compliance, cooperate with follow-up.
• Exclusion Criteria:
• • 1: Patients with known dMMR or MSI-H colorectal cancer who have not previously used anti-PD-1 or PD-L1 inhibitors
• • 2: Previously received small molecule targeted drug therapy with fuquinitinib
• • 3: Symptomatic brain or meningeal metastases (except those with brain metastases that have undergone local radiotherapy or surgery for more than 6 months and whose disease control is stable)
• • 4: Severe infection (such as intravenous infusion of antibiotics, antifungals, or antiviral drugs) within 4 weeks prior to treatment, or unexplained fever \> 38.5 ° C during screening/first administration
• • 5: Have high blood pressure that is not well controlled by antihypertensive medications (systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥100 mmHg)
• • 6: Obvious clinical bleeding symptoms or obvious bleeding tendency within 3 months prior to treatment (bleeding \> 30 mL within 3 months, hematemesis, black stool, blood in the stool), hemoptysis (\> 5 mL of fresh blood within 4 weeks), etc. Or treatment of arterial venous thrombosis events within the preceding 6 months, such as cerebrovascular accidents (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism
• • 7: Long-term anticoagulant therapy with warfarin or heparin, or long-term antiplatelet therapy (aspirin ≥300 mg/day or clopidogrel ≥75 mg/day) is required
• • 8: During screening, it was found that the tumor invaded large vascular structures, such as pulmonary artery, superior vena cava or inferior vena cava, etc., and the researchers judged that there was a risk of major bleeding
• • 9: The patient currently has gastrointestinal diseases such as active gastric and duodenal ulcers, ulcerative colitis, or active bleeding from unresectosed tumors, or other conditions determined by researchers that may cause gastrointestinal bleeding or perforation .Active heart disease, including myocardial infarction, severe/unstable angina, occurs 6 months before treatment. Left ventricular ejection fraction \<50% by echocardiography showed poor arrhythmia control.
• • 10: Patients with other malignant tumors (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix) in the past 5 years or at the same time
• • 11: Known allergy to the investigational drug or any of its excipients
• • 12: Active or uncontrolled severe infection
• • 1. Known human immunodeficiency virus (HIV) infection
• • 2. Known history of clinically significant liver disease, including viral hepatitis \[active HBV infection, i.e., positive HBV DNA (\>1×104 copies /mL or \>2000 IU/ml) must be excluded for known hepatitis B virus (HBV) carriers
• • 3. Known hepatitis C virus infection (HCV) and HCV RNA positive (\>1×103 copies /mL), or other hepatitis, cirrhosis\]
• • 13. Any other medical condition, clinically significant metabolic abnormality, physical abnormality or laboratory abnormality, in which, in the investigator's judgment, there is reason to suspect that the patient has a medical condition or condition that is not suitable for the use of the investigational drug (such as having seizures and requiring treatment), or which would affect the interpretation of the study results or place the patient at high risk
• • 14. Urine routine indicated urinary protein ≥2+, and 24-hour urinary protein quantity \>1.0g.
• • 15. Incomplete healing of skin wounds, surgical sites, trauma sites, severe mucosal ulcers or fractures
• • 16. Stroke events and/or transient cerebral ischemia occurred within 12 months prior to enrollment
• • 17. The patient has any current disease or condition that affects drug absorption, or the patient is unable to take fuquintinib orally
• • 18. Women who are pregnant (positive pregnancy test before medication) or breastfeeding
• • 19. The patients considered by the investigators to be unsuitable for inclusion in this study.